<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction Schema extraction-schema-10 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extraction Schema Details for extraction-schema-10</h1>

        <div class="section">
            <h2>Extraction Schema (General Information)</h2>
            <div class="info-section">
                <p><strong>Schema ID:</strong> extraction-schema-10</p>
                <p><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies evaluated to overcome late/acquired/secondary resistance to immune checkpoint inhibitors in melanoma. Capture clinical and preclinical evidence, patient/model context, prior immunotherapy exposure and resistance definitions, mechanistic rationale and targeted resistance mechanisms, biomarkers and their associations, treatment components and schedules, outcomes (responses, survival, intracranial control), safety, sequencing/rechallenge details, and notable limitations.</p>
            </div>
        </div>

        <div class="section">
            <h2>Extraction Schema (Details)</h2>
            <table>
                <thead>
                    <tr>
                        <th style="width: 20%;">Field Name</th>
                        <th style="width: 15%;">Type</th>
                        <th style="width: 65%;">Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>paper_title</strong></td>
                        <td>str</td>
                        <td>Full title of the paper.</td>
                    </tr>
                    <tr>
                        <td><strong>paper_year</strong></td>
                        <td>int</td>
                        <td>Year of publication (numeric if available).</td>
                    </tr>
                    <tr>
                        <td><strong>study_type</strong></td>
                        <td>str</td>
                        <td>Type of study: preclinical_in_vitro, preclinical_in_vivo, translational, case_report, retrospective_cohort, prospective_cohort, phase1, phase1b/2, phase2, phase3, meta_analysis, review (extract primary data if present).</td>
                    </tr>
                    <tr>
                        <td><strong>melanoma_subtype</strong></td>
                        <td>str</td>
                        <td>Melanoma subtype studied: cutaneous, mucosal, acral, uveal, mixed/unspecified.</td>
                    </tr>
                    <tr>
                        <td><strong>disease_setting</strong></td>
                        <td>str</td>
                        <td>Clinical context: metastatic/advanced, adjuvant, neoadjuvant, brain metastases cohort, oligoprogression, other.</td>
                    </tr>
                    <tr>
                        <td><strong>resistance_type</strong></td>
                        <td>str</td>
                        <td>Primary vs acquired/secondary vs late resistance; record exact term used.</td>
                    </tr>
                    <tr>
                        <td><strong>resistance_definition</strong></td>
                        <td>str</td>
                        <td>How the study defined acquired/late resistance (e.g., progression after initial CR/PR/SD lasting ≥6 months; iRECIST criteria; time thresholds).</td>
                    </tr>
                    <tr>
                        <td><strong>prior_immunotherapy</strong></td>
                        <td>str</td>
                        <td>Details of prior ICI(s): agents (e.g., anti–PD-1, anti–PD-L1, anti–CTLA-4), combinations, lines of therapy.</td>
                    </tr>
                    <tr>
                        <td><strong>best_prior_response</strong></td>
                        <td>str</td>
                        <td>Best response achieved before resistance (CR, PR, SD, duration if reported).</td>
                    </tr>
                    <tr>
                        <td><strong>time_on_prior_immunotherapy</strong></td>
                        <td>str</td>
                        <td>Exposure duration to prior ICI before progression (include units).</td>
                    </tr>
                    <tr>
                        <td><strong>time_to_progression_on_io</strong></td>
                        <td>str</td>
                        <td>Time from ICI start (or response) to progression indicating acquired resistance (include units).</td>
                    </tr>
                    <tr>
                        <td><strong>BRAF_NRAS_status</strong></td>
                        <td>str</td>
                        <td>Tumor mutation status relevant to targeted therapy (e.g., BRAF V600E/K, NRAS, NF1, wild-type).</td>
                    </tr>
                    <tr>
                        <td><strong>baseline_brain_metastases</strong></td>
                        <td>bool</td>
                        <td>Whether patients had brain metastases at baseline (true/false or null).</td>
                    </tr>
                    <tr>
                        <td><strong>number_of_prior_lines</strong></td>
                        <td>str</td>
                        <td>Number of prior systemic therapy lines (numeric if available).</td>
                    </tr>
                    <tr>
                        <td><strong>combination_strategy_name</strong></td>
                        <td>str</td>
                        <td>Short name of the combination strategy (e.g., nivolumab+relatlimab; ipilimumab+nivolumab salvage; TIL therapy (lifileucel) after PD-1; FMT+pembrolizumab).</td>
                    </tr>
                    <tr>
                        <td><strong>components_and_classes</strong></td>
                        <td>str</td>
                        <td>List all components with class/target (e.g., nivolumab [PD-1], ipilimumab [CTLA-4], relatlimab [LAG-3], T-VEC [oncolytic virus], radiotherapy 30 Gy/10 fx).</td>
                    </tr>
                    <tr>
                        <td><strong>dosing_schedule</strong></td>
                        <td>str</td>
                        <td>Doses, schedules, routes for each component; include sequencing (concurrent vs sequential) if embedded in dosing.</td>
                    </tr>
                    <tr>
                        <td><strong>sequencing_timing</strong></td>
                        <td>str</td>
                        <td>Therapy sequence relative to prior ICI: immediate salvage, delayed rechallenge, switch to targeted then reintroduce ICI, maintenance strategies; intervals/time gaps.</td>
                    </tr>
                    <tr>
                        <td><strong>local_therapy_context</strong></td>
                        <td>str</td>
                        <td>Use of local treatments with systemic therapy (e.g., stereotactic radiosurgery for oligoprogression while continuing PD-1; intratumoral injections).</td>
                    </tr>
                    <tr>
                        <td><strong>rationale_mechanism</strong></td>
                        <td>str</td>
                        <td>Mechanistic rationale for the combo (e.g., augment priming via CTLA-4, reverse T cell exhaustion via LAG-3, increase antigenicity via epigenetic drugs, inflame tumor via oncolytic/STING).</td>
                    </tr>
                    <tr>
                        <td><strong>resistance_mechanism_addressed</strong></td>
                        <td>str</td>
                        <td>Specific resistance mechanisms targeted/observed: B2M/HLA loss, JAK1/2 IFN signaling defects, antigen loss/dedifferentiation (MITF-low/AXL-high), WNT/β-catenin, PTEN loss/PI3K, myeloid immunosuppression (MDSC/TAM), Treg dominance, adenosine/CD73, IDO, VEGF-mediated exclusion, microbiome-related nonresponsiveness.</td>
                    </tr>
                    <tr>
                        <td><strong>biomarkers_measured</strong></td>
                        <td>str</td>
                        <td>List of biomarkers assessed: PD-L1, TMB, gene signatures (IFN-γ), HLA class I, B2M/JAK mutations, ctDNA, TCR clonality, microbiome taxa, spatial immune profiling, LDH, AXL/MITF states, others.</td>
                    </tr>
                    <tr>
                        <td><strong>biomarker_associations</strong></td>
                        <td>str</td>
                        <td>Associations between biomarkers/resistance mechanisms and outcomes to the combination (e.g., B2M loss predicts poor ICI rechallenge; microbiome composition predicts response to FMT+PD-1).</td>
                    </tr>
                    <tr>
                        <td><strong>outcomes_summary</strong></td>
                        <td>str</td>
                        <td>Brief, dense summary of efficacy outcomes and key numbers for the combo in the resistant population.</td>
                    </tr>
                    <tr>
                        <td><strong>ORR</strong></td>
                        <td>str</td>
                        <td>Objective response rate with units/percent and CI if available; specify if in PD-1-refractory subset.</td>
                    </tr>
                    <tr>
                        <td><strong>CR_rate</strong></td>
                        <td>str</td>
                        <td>Complete response rate (percent, CI if available).</td>
                    </tr>
                    <tr>
                        <td><strong>DCR</strong></td>
                        <td>str</td>
                        <td>Disease control rate (percent).</td>
                    </tr>
                    <tr>
                        <td><strong>PFS</strong></td>
                        <td>str</td>
                        <td>Progression-free survival (median, months, HR/CI if comparative).</td>
                    </tr>
                    <tr>
                        <td><strong>OS</strong></td>
                        <td>str</td>
                        <td>Overall survival (median, months, HR/CI if comparative).</td>
                    </tr>
                    <tr>
                        <td><strong>DoR</strong></td>
                        <td>str</td>
                        <td>Duration of response (median, months) if reported.</td>
                    </tr>
                    <tr>
                        <td><strong>intracranial_outcomes</strong></td>
                        <td>str</td>
                        <td>Outcomes for brain metastases if reported (intracranial ORR, PFS, local control).</td>
                    </tr>
                    <tr>
                        <td><strong>response_by_biomarker_subgroup</strong></td>
                        <td>str</td>
                        <td>Efficacy stratified by biomarkers/resistance mechanism (e.g., PD-L1+, BRAF-mutant, presence of B2M mutation).</td>
                    </tr>
                    <tr>
                        <td><strong>comparator_and_results</strong></td>
                        <td>str</td>
                        <td>If a comparator arm exists (e.g., ipi alone vs ipi+nivo salvage), summarize comparator and relative results (HRs, p-values).</td>
                    </tr>
                    <tr>
                        <td><strong>rechallenge_specifics_and_results</strong></td>
                        <td>str</td>
                        <td>Details and outcomes for ICI rechallenge strategies (e.g., PD-1 reinitiation +/- CTLA-4, interval off therapy).</td>
                    </tr>
                    <tr>
                        <td><strong>safety_grade3plus_AEs</strong></td>
                        <td>str</td>
                        <td>Rates and types of grade ≥3 treatment-related adverse events.</td>
                    </tr>
                    <tr>
                        <td><strong>treatment_related_mortality</strong></td>
                        <td>str</td>
                        <td>Number/percent of treatment-related deaths, if any.</td>
                    </tr>
                    <tr>
                        <td><strong>discontinuation_rate</strong></td>
                        <td>str</td>
                        <td>Rate of treatment discontinuation due to AEs.</td>
                    </tr>
                    <tr>
                        <td><strong>notable_toxicities</strong></td>
                        <td>str</td>
                        <td>Specific toxicities of note (e.g., hepatitis, colitis, cytokine-mediated toxicities, neurotoxicity, autoimmune events).</td>
                    </tr>
                    <tr>
                        <td><strong>sample_size</strong></td>
                        <td>str</td>
                        <td>Number of patients/animals analyzed for the resistant cohort; include subgroup sizes where relevant.</td>
                    </tr>
                    <tr>
                        <td><strong>trial_name_or_NCT</strong></td>
                        <td>str</td>
                        <td>Trial identifier (e.g., NCT number) or study acronym/name if applicable.</td>
                    </tr>
                    <tr>
                        <td><strong>preclinical_model</strong></td>
                        <td>str</td>
                        <td>For preclinical studies: model system (e.g., B16F10 murine melanoma, PDX, syngeneic models), genetic alterations, and resistance modeling approach.</td>
                    </tr>
                    <tr>
                        <td><strong>preclinical_results</strong></td>
                        <td>str</td>
                        <td>Key preclinical efficacy results (tumor growth inhibition/regression, survival benefit, synergy metrics) with numbers.</td>
                    </tr>
                    <tr>
                        <td><strong>immune_correlates</strong></td>
                        <td>str</td>
                        <td>Changes in TME/immune contexture with the combo (e.g., CD8+ T cell infiltration, Treg/MDSC shifts, cytokines, IFN signaling, antigen presentation).</td>
                    </tr>
                    <tr>
                        <td><strong>limitations</strong></td>
                        <td>str</td>
                        <td>Study limitations relevant to inference (small sample, single-arm, selection bias, heterogeneous definitions of resistance, negative/neutral results).</td>
                    </tr>
                    <tr>
                        <td><strong>evidence_level</strong></td>
                        <td>str</td>
                        <td>Evidence strength category (e.g., high: randomized phase 3; moderate: phase 2/robust translational; low: retrospective/case series; preclinical).</td>
                    </tr>
                    <tr>
                        <td><strong>key_quote</strong></td>
                        <td>str</td>
                        <td>A concise verbatim sentence from the paper that encapsulates the main finding about overcoming acquired resistance.</td>
                    </tr>
                    <tr>
                        <td><strong>notes</strong></td>
                        <td>str</td>
                        <td>Any additional details aiding theory building (e.g., context on microbiome donors in FMT, epigenetic drug class specifics, radiotherapy dose/fractionation, site-specific effects).</td>
                    </tr>
                </tbody>
            </table>
        </div>

    </div>
</body>
</html>